Extended-Release Tramadol May Ease Opioid Withdrawal Symptoms — Physician’s First Watch

Medical News |
July 13, 2017

Extended-Release Tramadol May Ease Opioid Withdrawal Symptoms

By Kelly Young

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM

Extended-release tramadol may help reduce withdrawal symptoms in patients being treated for opioid use disorder, according to a JAMA Psychiatry study partly funded by industry.

Roughly 100 adults with opioid use disorder were stabilized with morphine for 7–10 days in a residential research facility. During the subsequent 7-day taper phase, they were randomized to receive clonidine, buprenorphine, or extended-release tramadol (a Schedule V medication and opioid agonist) four times a day. In the post-taper phase, all participants received placebo capsules and tablets.

During the taper phase, tramadol recipients had fewer withdrawal symptoms than clonidine recipients and about the same as buprenorphine recipients. In addition, tramadol recipients did not have a delayed onset of opioid withdrawal during the post-taper phase.

The authors say that the findings "empirically support the use and further evaluation of tramadol ER for medically supervised opioid withdrawal."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.